Cn /En

News Center

——

Company news

Industry news

InnoModels Biotechnology: CDC in vitro immune-tumour cell co-culture killing experimental platform

Author:

InnoModels Biotechnology

Release time:

2024-01-10

InnoModels Biotechnology has long been committed to advancing research and development in the field of antibody-dependent cytotoxicity (ADCC) in order to improve the efficacy of cancer therapies. In this journey of discovery, we are proud to introduce the innovative CDC In Vitro Immuno-Tumour Cell Co-Culture Killing Experiment Platform, which provides researchers with a powerful and precise tool that promises to drive innovation in cancer treatment.
Experimental platform features
1. Simulates in vivo environment:
The CDC in vitro immune-tumour cell co-culture and killing experimental platform can simulate the complex immune microenvironment in vivo, providing an experimental system that is closer to real physiological conditions. This helps to more accurately assess the effects of potential therapeutic drugs in the immune system.
2. Accurate simulation of immune cell interactions:
The experimental platform enables complex interactions between antibodies, immune cells and tumour cells through carefully designed in vitro conditions. This includes clever simulations of antibody binding to tumour cells, immune cell activation and killing processes, enabling researchers to gain a more comprehensive understanding of the mechanisms of ADCC.
3. High-throughput automation:
To improve experimental efficiency, our platform employs high-throughput automation technology, which is capable of processing multiple samples simultaneously for large-scale data collection and analysis. This enables researchers to assess the effects of different treatment regimens more quickly and comprehensively.
4. Flexibility and customisation:
Our platform is designed to be flexible and can be customised according to the needs of researchers. This allows experiments to be better adapted to different cancer types and individual patient differences, supporting the development of personalised treatment plans.

Application Areas
The CDC in vitro immune-tumour cell co-culture killing experimental platform has a wide range of applications in cancer therapy research, including but not limited to:
Drug screening and evaluation:
Rapidly and accurately assess the ADCC effects of potential therapeutic agents, providing important information for drug development.
Mechanistic studies:
In-depth exploration of the molecular mechanisms of ADCC, revealing the interaction between therapeutic agents and the immune system.
Personalised therapy:
Tailor the treatment plan based on patients' immune characteristics to improve the relevance and efficacy of treatment.
Biomarker Identification:
Discover and validate biomarkers associated with the effects of ADCC, providing a basis for clinical translation.
Conclusion.
The launch of the CDC in vitro immune-tumour cell co-culture killing experimental platform marks the unremitting efforts of InnoModels Biotechnology in the field of ADCC research. We believe that the wide application of this platform will open a brand new chapter for the future of cancer treatment, provide patients with more personalised and precise treatment plans, and help medical science and technology to move forward.

InnoModels Biotechnology: Cutting-edge breakthroughs in immune co-culture killing models

InnoModels Biotechnology: Focus on Antibody-Dependent Cellular Cytotoxicity (ADCC) Research

InnoModels Biotechnology: Cutting-edge breakthroughs in immune co-culture killing models

InnoModels Biotechnology: Focus on Antibody-Dependent Cellular Cytotoxicity (ADCC) Research

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License